{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:06:19Z","timestamp":1784696779429,"version":"3.55.0"},"reference-count":39,"publisher":"BMJ","funder":[{"DOI":"10.13039\/501100013342","name":"Imperial Biomedical Research Centre","doi-asserted-by":"crossref","award":["no grant number"],"award-info":[{"award-number":["no grant number"]}],"id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Royal Brompton Clinical Research Facility","award":["No grant number"],"award-info":[{"award-number":["No grant number"]}]},{"DOI":"10.13039\/501100000272","name":"National Institute of Health Research","doi-asserted-by":"crossref","award":["No grant number"],"award-info":[{"award-number":["No grant number"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["0208A120"],"award-info":[{"award-number":["0208A120"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["MCNALL19K0"],"award-info":[{"award-number":["MCNALL19K0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023551","name":"Cystic Fibrosis Ireland","doi-asserted-by":"publisher","award":["VIA083"],"award-info":[{"award-number":["VIA083"]}],"id":[{"id":"10.13039\/501100023551","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000292","name":"Cystic Fibrosis Trust","doi-asserted-by":"publisher","award":["RECOVER01"],"award-info":[{"award-number":["RECOVER01"]}],"id":[{"id":"10.13039\/501100000292","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2026,4,29]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      The current cystic fibrosis (CF) care era, while hugely welcome, raises new challenges, particularly the need for more sensitive pulmonary outcome measures. Seeking further optimisation, we previously developed a Short extension to multiple breath washout measure (MBW\n                      <jats:sub>ShX<\/jats:sub>\n                      ) which captures previously overlooked, under-ventilated lung units but lacks regional information. Functional lung MRI addresses this limitation. We hypothesised these measures would be more sensitive to change in tracking CF lung disease than usual clinical respiratory function tests.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Forty-six people with (pw)CF, median age 15 (range 6\u201355) years were recruited to a single-centre study. While clinically stable, pwCF performed OE-MRI, MBW+\/-\n                      <jats:sub>ShX<\/jats:sub>\n                      and spirometry at baseline and at 6 monthly intervals over 18\u2009months of follow-up. A subgroup of pwCF (n=20) and age-matched healthy controls (HC, n=20) performed two repeatability visits within 6\u2009weeks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      OE-MRI\/MBW\n                      <jats:sub>ShX<\/jats:sub>\n                      were well tolerated, differentiated HC and CF groups, and were repeatable with negligible differences between two visits &lt;6\u2009weeks apart. OE-MRI\/MBW\n                      <jats:sub>ShX<\/jats:sub>\n                      parameters worsened at 12\u2009months (p&lt;0.05) and 18\u2009months (p&lt;0.01). In contrast, conventional measures of pulmonary function (FEV\n                      <jats:sub>1<\/jats:sub>\n                      + LCI\n                      <jats:sub>2.5<\/jats:sub>\n                      ) did not change significantly.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      OE-MRI\/MBW\n                      <jats:sub>ShX<\/jats:sub>\n                      are novel, sensitive tools to track progression of abnormalities in lung structure\/function. Such progression may not be detected by conventional outcome measures. CF transmembrane conductance regulator (CFTR) modulators have been transformative for many pwCF and generally lead to substantial improvements in lung health. Stable FEV\n                      <jats:sub>1<\/jats:sub>\n                      over longer time periods and, during mucoactive treatment withdrawal, may give false reassurance. OE-MRI\/MBW\n                      <jats:sub>ShX<\/jats:sub>\n                      reveal the likely less welcome reality that lung-disease progresses despite CFTR modulators. These measures could be considered in future studies when enhanced sensitivity is required.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2025-224648","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:25:15Z","timestamp":1780482315000},"page":"thorax-2025-224648","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Oxygen-enhanced MRI and multiple breath washout with Short extension reveal cystic fibrosis lung disease progression despite triple modulator therapy"],"prefix":"10.1136","clinical-trial-number":[{"clinical-trial-number":"nct04602468","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3131-7639","authenticated-orcid":false,"given":"Christopher","family":"Short","sequence":"first","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, England, UK"},{"name":"Royal Brompton and Harefield Hospitals, Guy's and St Thomas\u2019 Hospitals NHS Trust, London, England, UK"},{"name":"Lung Clearance Index Core Facility, European Cystic Fibrosis Society, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3740-6429","authenticated-orcid":false,"given":"Tom","family":"Semple","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, England, UK"},{"name":"Royal Brompton and Harefield Hospitals, Guy's and St Thomas\u2019 Hospitals NHS Trust, London, England, UK"},{"name":"Centre for Paediatrics and Child Health, Imperial College London, London, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Abkir","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, England, UK"},{"name":"Royal Brompton and Harefield Hospitals, Guy's and St Thomas\u2019 Hospitals NHS Trust, London, England, UK"},{"name":"Lung Clearance Index Core Facility, European Cystic Fibrosis Society, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos","family":"Efthyvoulou","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Padley","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, England, UK"},{"name":"Royal Brompton and Harefield Hospitals, Guy's and St Thomas\u2019 Hospitals NHS Trust, London, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, England, UK"},{"name":"Royal Brompton and Harefield Hospitals, Guy's and St Thomas\u2019 Hospitals NHS Trust, London, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7102-1712","authenticated-orcid":false,"given":"Paul","family":"McNally","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Royal College of Surgeons in Ireland, Dublin, Ireland"},{"name":"Department of Respiratory Medicine, Children\u2019s Health Ireland, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm","family":"Tiddens","sequence":"additional","affiliation":[{"name":"Department of Paediatric Pulmonology and Allergology, Erasmus MC -Sophia Children\u2019s Hospital, Rotterdam, Netherlands"},{"name":"Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, Netherlands"},{"name":"Thirona, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan","family":"Caudri","sequence":"additional","affiliation":[{"name":"Department of Paediatric Pulmonology and Allergology, Erasmus MC -Sophia Children\u2019s Hospital, Rotterdam, Netherlands"},{"name":"Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Tibiletti","sequence":"additional","affiliation":[{"name":"Bioxydyn Ltd, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff J","family":"Parker","sequence":"additional","affiliation":[{"name":"Bioxydyn Ltd, Manchester, UK"},{"name":"Department of Medical Physics & Biomedical Engineering, University College London, London, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3506-1199","authenticated-orcid":false,"given":"Jane Carolyn","family":"Davies","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, England, UK"},{"name":"Royal Brompton and Harefield Hospitals, Guy's and St Thomas\u2019 Hospitals NHS Trust, London, England, UK"},{"name":"Lung Clearance Index Core Facility, European Cystic Fibrosis Society, London, UK"},{"name":"Centre for Paediatrics and Child Health, Imperial College London, London, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"2026060303250589000_thorax-2025-224648v1.1","article-title":"Forced Expiratory Volume in 1 second is an unreliable marker of risk of death in the next 2 years","volume":"S19","author":"Robinson","year":"1999","journal-title":"Pediatr Pulmonol"},{"key":"2026060303250589000_thorax-2025-224648v1.2","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jcf.2020.10.007","article-title":"Utility of lung clearance index in CF: What we know, what we don\u2019t know and musings on how to bridge the gap","volume":"19","author":"Short","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026060303250589000_thorax-2025-224648v1.3","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S2213-2600(13)70182-6","article-title":"Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial","volume":"1","author":"Davies","year":"2013","journal-title":"Lancet Respir Med"},{"key":"2026060303250589000_thorax-2025-224648v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.06.013"},{"key":"2026060303250589000_thorax-2025-224648v1.5","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.00340.2024"},{"key":"2026060303250589000_thorax-2025-224648v1.6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201501-0061OC"},{"key":"2026060303250589000_thorax-2025-224648v1.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.prrv.2006.04.005"},{"key":"2026060303250589000_thorax-2025-224648v1.8","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-006-0311-5"},{"key":"2026060303250589000_thorax-2025-224648v1.9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1164\/rccm.201705-0894LE","article-title":"Longitudinal Assessment of Children with Mild Cystic Fibrosis Using Hyperpolarized Gas Lung Magnetic Resonance Imaging and Lung Clearance Index","volume":"197","author":"Smith","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026060303250589000_thorax-2025-224648v1.10","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1007\/s00330-018-5383-5","article-title":"Volumetric dynamic oxygen-enhanced MRI (OE-MRI): comparison with CT Brody score and lung function in cystic fibrosis patients","volume":"28","author":"Martini","year":"2018","journal-title":"Eur Radiol"},{"key":"2026060303250589000_thorax-2025-224648v1.11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2214\/ajr.177.1.1770185","article-title":"Oxygen-enhanced MR ventilation imaging of the lung: preliminary clinical experience in 25 subjects","volume":"177","author":"Ohno","year":"2001","journal-title":"AJR Am J Roentgenol"},{"key":"2026060303250589000_thorax-2025-224648v1.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2024-002784","article-title":"T2*-weighted oxygen-enhanced pulmonary MRI in COPD is linked to resting and exertional functional measurements","volume":"12","author":"Elbehairy","year":"2025","journal-title":"BMJ Open Respir Res"},{"key":"2026060303250589000_thorax-2025-224648v1.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2026060303250589000_thorax-2025-224648v1.14","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A Phase 3 Open-Label Study of Elexacaftor\/Tezacaftor\/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026060303250589000_thorax-2025-224648v1.15","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.70083","article-title":"Improved Clinical Outcomes With Elexacaftor\/Tezacaftor\/Ivacaftor in Patients With Cystic Fibrosis and Advanced Lung Disease: Real\u2010World Evidence From an Italian Single\u2010Center Study","volume":"13","author":"Perrotta","year":"2025","journal-title":"Pharmacology Res & Perspec"},{"key":"2026060303250589000_thorax-2025-224648v1.16","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2023-220100"},{"key":"2026060303250589000_thorax-2025-224648v1.17","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00434-9"},{"key":"2026060303250589000_thorax-2025-224648v1.18","doi-asserted-by":"crossref","first-page":"S73a","DOI":"10.1016\/S1569-1993(25)01745-X","article-title":"126 Registry-based RCT to assess change in respiratory function for people with cystic fibrosis established on elexacaftor\/tezacaftor\/ivacaftor after withdrawal of nebulised mucoactive therapies: CF STORM","volume":"24","author":"Davies","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026060303250589000_thorax-2025-224648v1.19","doi-asserted-by":"crossref","unstructured":"Sagel SD , Vu P , Heltshe SL , et al . Elexacaftor\/tezacaftor\/ivacaftor is associated with long-term reduction in use of chronic respiratory therapies in cystic fibrosis. J Cyst Fibros 2025. doi:10.1016\/j.jcf.2025.11.016","DOI":"10.1016\/j.jcf.2025.11.016"},{"key":"2026060303250589000_thorax-2025-224648v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-1993(02)00141-8"},{"key":"2026060303250589000_thorax-2025-224648v1.21","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00069712"},{"key":"2026060303250589000_thorax-2025-224648v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.11.006"},{"key":"2026060303250589000_thorax-2025-224648v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2011.02.045"},{"key":"2026060303250589000_thorax-2025-224648v1.24","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/mrm.29914","article-title":"Feasibility of dynamic T 2 *\u2010based oxygen\u2010enhanced lung MRI at 3T","volume":"91","author":"Kim","year":"2024","journal-title":"Magnetic Resonance in Med"},{"key":"2026060303250589000_thorax-2025-224648v1.25","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.radi.2022.02.010","article-title":"Review of claustrophobia incidence in MRI: A service evaluation of current rates across a multi-centre service","volume":"28","author":"Hudson","year":"2022","journal-title":"Radiography (Lond)"},{"key":"2026060303250589000_thorax-2025-224648v1.26","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2021-218347"},{"key":"2026060303250589000_thorax-2025-224648v1.27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2024-002456","article-title":"Definitions of pulmonary exacerbation in people with cystic fibrosis: a scoping review","volume":"11","author":"Almulhem","year":"2024","journal-title":"BMJ Open Respir Res"},{"key":"2026060303250589000_thorax-2025-224648v1.28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/ACI.0b013e32810fd771","article-title":"Predicting asthma control and exacerbations: chronic asthma as a complex dynamic model","volume":"7","author":"Frey","year":"2007","journal-title":"Current Opinion in Allergy & Clinical Immunology"},{"key":"2026060303250589000_thorax-2025-224648v1.29","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1164\/rccm.202102-0278OC","article-title":"Magnetic Resonance Imaging Detects Progression of Lung Disease and Impact of Newborn Screening in Preschool Children with Cystic Fibrosis","volume":"204","author":"Stahl","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026060303250589000_thorax-2025-224648v1.30","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ppul.24646","article-title":"Mucus plugging, air trapping, and bronchiectasis are important outcome measures in assessing progressive childhood cystic fibrosis lung disease","volume":"55","author":"Robinson","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"2026060303250589000_thorax-2025-224648v1.31","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/rccm.202308-1317OC","article-title":"Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor\/Tezacaftor\/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older - The RECOVER Trial","volume":"208","author":"McNally","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026060303250589000_thorax-2025-224648v1.32","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00211914"},{"key":"2026060303250589000_thorax-2025-224648v1.33","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02029-2022","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study","volume":"62","author":"Daines","year":"2023","journal-title":"Eur Respir J"},{"key":"2026060303250589000_thorax-2025-224648v1.34","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-200912"},{"key":"2026060303250589000_thorax-2025-224648v1.35","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1513\/AnnalsATS.202505-497RL","article-title":"Xenon-129 magnetic resonance imaging detects ongoing ventilation improvements in people with cystic fibrosis receiving highly effective modulator therapy","volume":"23","author":"Hussain","year":"2026","journal-title":"Ann Am Thorac Soc"},{"key":"2026060303250589000_thorax-2025-224648v1.36","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201507-1281OC"},{"key":"2026060303250589000_thorax-2025-224648v1.37","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21117"},{"key":"2026060303250589000_thorax-2025-224648v1.38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127742","article-title":"Pseudomonas aeruginosa Reduces VX-809 Stimulated F508del-CFTR Chloride Secretion by Airway Epithelial Cells","volume":"10","author":"Stanton","year":"2015","journal-title":"PLoS One"},{"key":"2026060303250589000_thorax-2025-224648v1.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.05.015"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2025-224648","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:25:21Z","timestamp":1780482321000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2025-224648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":39,"alternative-id":["10.1136\/thorax-2025-224648"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2025-224648","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]}}}